US Stock MarketDetailed Quotes
CARA Cara Therapeutics
- 0.345
- +0.034+10.83%
Close Nov 7 16:00 ET
- 0.345
- 0.0000.00%
Post 17:15 ET
18.92MMarket Cap-169P/E (TTM)
0.357High0.312Low2.85MVolume0.320Open0.311Pre Close985.30KTurnover6.09%Turnover RatioLossP/E (Static)54.85MShares1.31052wk High1.64P/B16.14MFloat Cap0.24052wk Low--Dividend TTM46.78MShs Float29.647Historical High--Div YieldTTM14.46%Amplitude0.240Historical Low0.345Avg Price1Lot Size
About Cara Therapeutics Company
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Company Profile
SymbolCARA
Company NameCara Therapeutics
Listing DateJan 31, 2014
Issue Price11.00
Founded2004
CEOMr. Christopher A. Posner
MarketNASDAQ
Employees55
Fiscal Year Ends12-31
Address400 Atlantic Street,Suite 500
CityStamford
ProvinceConnecticut
CountryUnited States of America
Zip Code06901
Phone1-203-406-3700
Company Executives
- Name
- Position
- Salary
- Christopher A. Posner
- President, Chief Executive Officer and Director
- 2.92M
- Scott M. Terrillion
- General Counsel, Secretary and Chief Compliance Officer
- --
- Ryan D. Maynard
- Chief Financial Officer and Principal Accounting Officer
- 1.24M
- Martin A. Vogelbaum
- Chairman of the Board
- 519.99K
- Dr. Lisa von Moltke, M.D.
- Independent Director
- 254.99K
- Dr. Jeffrey L. Ives, PhD
- Independent Director
- 272.49K
- Dr. Susan Shiff, M.B.A.,PhD
- Independent Director
- 262.49K
- Helen M. Boudreau, M.B.A.
- Independent Director
- 376.01K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data